BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Extra | May 19, 2015
Company News

Management tracks

Endocrine company Chiasma Inc. (Jerusalem, Israel) hired Mark Fitzpatrick as CFO, effective June 10. Fitzpatrick was CFO of rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), where Chief Accounting Officer David Aubuchon will succeed him as...
BC Week In Review | Nov 24, 2014
Financial News

Reva Medical completes private placement of convertible notes

Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Business: Cardiovascular, Diagnostic   Date completed: 2014-11-20   Type: Private placement of convertible notes   Raised: $25 million   Shares outstanding prior: 33.5 million   Investors: Goldman...
BC Week In Review | Feb 17, 2014
Company News

Reva Medical management update

Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Business: Cardiovascular, Diagnostic   Hired: David Eisler as VP and general counsel, formerly SVP, general counsel and corporate secretary at The Active Network Inc.  ...
BC Week In Review | Jan 27, 2014
Clinical News

ReZolve2: Completed pivotal trial enrollment

Reva completed enrollment of 112 patients in the international pivotal RESTORE II trial evaluating the ReZolve2 stent. The company plans to present data at the Paris Course on Revascularization meeting in Paris in May. Reva...
BC Week In Review | Apr 8, 2013
Clinical News

ReZolve2: Pivotal trial started

Reva began the international pivotal RESTORE II trial to evaluate the ReZolve2 stent in up to 125 patients. Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Product: ReZolve2   Business: Cardiovascular   Molecular target: NA...
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
BC Week In Review | Jul 23, 2012
Clinical News

ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Completed pilot trial enrollment

Reva completed enrollment of 26 patients with symptomatic coronary artery disease due to one or more discrete areas of blockage in the open-label, international RESTORE pilot trial evaluating ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold. The company...
BC Week In Review | Jan 9, 2012
Clinical News

ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Pilot trial started

Reva began the open-label, international RESTORE pilot trial to evaluate the ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold in 50 patients with symptomatic coronary artery disease due to one or more discrete areas of blockage. Reva Medical...
BioCentury | Sep 12, 2011
Finance

Playing chess

Playing chess Massachusetts-based GI Dynamics Inc. (ASX:GID) opted to price its IPO on the Australian Securities Exchange on the advice of board members with experience listing U.S. life sciences companies on the ASX. A driver...
Items per page:
1 - 10 of 14
BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Extra | May 19, 2015
Company News

Management tracks

Endocrine company Chiasma Inc. (Jerusalem, Israel) hired Mark Fitzpatrick as CFO, effective June 10. Fitzpatrick was CFO of rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), where Chief Accounting Officer David Aubuchon will succeed him as...
BC Week In Review | Nov 24, 2014
Financial News

Reva Medical completes private placement of convertible notes

Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Business: Cardiovascular, Diagnostic   Date completed: 2014-11-20   Type: Private placement of convertible notes   Raised: $25 million   Shares outstanding prior: 33.5 million   Investors: Goldman...
BC Week In Review | Feb 17, 2014
Company News

Reva Medical management update

Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Business: Cardiovascular, Diagnostic   Hired: David Eisler as VP and general counsel, formerly SVP, general counsel and corporate secretary at The Active Network Inc.  ...
BC Week In Review | Jan 27, 2014
Clinical News

ReZolve2: Completed pivotal trial enrollment

Reva completed enrollment of 112 patients in the international pivotal RESTORE II trial evaluating the ReZolve2 stent. The company plans to present data at the Paris Course on Revascularization meeting in Paris in May. Reva...
BC Week In Review | Apr 8, 2013
Clinical News

ReZolve2: Pivotal trial started

Reva began the international pivotal RESTORE II trial to evaluate the ReZolve2 stent in up to 125 patients. Reva Medical Inc. (ASX:RVA), San Diego, Calif.   Product: ReZolve2   Business: Cardiovascular   Molecular target: NA...
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
BC Week In Review | Jul 23, 2012
Clinical News

ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Completed pilot trial enrollment

Reva completed enrollment of 26 patients with symptomatic coronary artery disease due to one or more discrete areas of blockage in the open-label, international RESTORE pilot trial evaluating ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold. The company...
BC Week In Review | Jan 9, 2012
Clinical News

ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold: Pilot trial started

Reva began the open-label, international RESTORE pilot trial to evaluate the ReZolve Bioresorbable Sirolimus-Eluting Coronary Scaffold in 50 patients with symptomatic coronary artery disease due to one or more discrete areas of blockage. Reva Medical...
BioCentury | Sep 12, 2011
Finance

Playing chess

Playing chess Massachusetts-based GI Dynamics Inc. (ASX:GID) opted to price its IPO on the Australian Securities Exchange on the advice of board members with experience listing U.S. life sciences companies on the ASX. A driver...
Items per page:
1 - 10 of 14